<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6405095</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0213190</article-id><article-id pub-id-type="publisher-id">PONE-D-18-26261</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Mathematical Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Filoviruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Hemorrhagic Fever Viruses</subject><subj-group><subject>Ebola Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Viral Hemorrhagic Fevers</subject><subj-group><subject>Ebola Hemorrhagic Fever</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Viral Hemorrhagic Fevers</subject><subj-group><subject>Ebola Hemorrhagic Fever</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Probability Theory</subject><subj-group><subject>Probability Distribution</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Projections of Ebola outbreak size and duration with and without vaccine use in &#x000c9;quateur, Democratic Republic of Congo, as of May 27, 2018</article-title><alt-title alt-title-type="running-head">Projections of the 2018 Ebola outbreak size and duration</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>J. Daniel</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9799-0183</contrib-id><name><surname>Worden</surname><given-names>Lee</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4387-3966</contrib-id><name><surname>Wannier</surname><given-names>S. Rae</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoff</surname><given-names>Nicole A.</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mukadi</surname><given-names>Patrick</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sinai</surname><given-names>Cyrus</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ackley</surname><given-names>Sarah</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xianyun</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Daozhou</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Selo</surname><given-names>Bernice</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mossoko</surname><given-names>Mathais</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Okitolonda-Wemakoy</surname><given-names>Emile</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Eugene T.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rutherford</surname><given-names>George W.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lietman</surname><given-names>Thomas M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Muyembe-Tamfum</surname><given-names>Jean Jacques</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rimoin</surname><given-names>Anne W.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Porco</surname><given-names>Travis C.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>School of Medicine, University of California, San Francisco (UCSF), San Francisco, CA, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>F.I. Proctor Foundation, UCSF, San Francisco, CA, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States of America</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Mathematics and Science College, Shanghai Normal University, Shanghai, China</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Ministry of Health, Kinshasa, Democratic Republic of Congo</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of Congo</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Harvard Medical School, Boston, MA, United States of America</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Brigham and Women&#x02019;s Hospital, Boston, MA, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Schieffelin</surname><given-names>John</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Tulane University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>dan.kelly@ucsf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>3</issue><elocation-id>e0213190</elocation-id><history><date date-type="received"><day>7</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Kelly et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Kelly et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0213190.pdf"/><abstract><p>As of May 27, 2018, 6 suspected, 13 probable and 35 confirmed cases of Ebola virus disease (EVD) had been reported in &#x000c9;quateur Province, Democratic Republic of Congo. We used reported case counts and time series from prior outbreaks to estimate the total outbreak size and duration with and without vaccine use. We modeled Ebola virus transmission using a stochastic branching process model that included reproduction numbers from past Ebola outbreaks and a particle filtering method to generate a probabilistic projection of the outbreak size and duration conditioned on its reported trajectory to date; modeled using high (62%), low (44%), and zero (0%) estimates of vaccination coverage (after deployment). Additionally, we used the time series for 18 prior Ebola outbreaks from 1976 to 2016 to parameterize the Thiel-Sen regression model predicting the outbreak size from the number of observed cases from April 4 to May 27. We used these techniques on probable and confirmed case counts with and without inclusion of suspected cases. Probabilistic projections were scored against the actual outbreak size of 54 EVD cases, using a log-likelihood score. With the stochastic model, using high, low, and zero estimates of vaccination coverage, the median outbreak sizes for probable and confirmed cases were 82 cases (95% prediction interval [PI]: 55, 156), 104 cases (95% PI: 58, 271), and 213 cases (95% PI: 64, 1450), respectively. With the Thiel-Sen regression model, the median outbreak size was estimated to be 65.0 probable and confirmed cases (95% PI: 48.8, 119.7). Among our three mathematical models, the stochastic model with suspected cases and high vaccine coverage predicted total outbreak sizes closest to the true outcome. Relatively simple mathematical models updated in real time may inform outbreak response teams with projections of total outbreak size and duration.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>U01- GM087728</award-id><principal-award-recipient><name><surname>Porco</surname><given-names>Travis C.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>U01- GM087728</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9799-0183</contrib-id><name><surname>Worden</surname><given-names>Lee</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Faucett Catalyst Fund</institution></funding-source><principal-award-recipient><name><surname>Rimoin</surname><given-names>Anne W.</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the National Institute of General Medical Sciences, U01- GM087728, Dr. Lee Worden, Dr. Travis C Porco; Faucett Catalyst Fund, Dr. Anne W Rimoin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Timeseries data is fully plotted in the manuscript figures. These data are also available from <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.7598873.v1">https://doi.org/10.6084/m9.figshare.7598873.v1</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Timeseries data is fully plotted in the manuscript figures. These data are also available from <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.7598873.v1">https://doi.org/10.6084/m9.figshare.7598873.v1</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>On May 8, 2018, the World Health Organization (WHO) announced the occurrence of an outbreak of Ebola virus disease (EVD) in the Democratic Republic of Congo (DRC).[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>] From April 4 through May 7, 21 suspected EVD cases were reported in Iboko and Bikoro, &#x000c9;quateur Province. On May 7, blood samples from five hospitalized patients had been sent to Kinshasa for Ebola-PCR testing, and two were confirmed PCR-positive.[<xref rid="pone.0213190.ref002" ref-type="bibr">2</xref>] On May 21, vaccination of healthcare workers started.[<xref rid="pone.0213190.ref003" ref-type="bibr">3</xref>] By May 27, the ring vaccination campaign was being rolled out as 906 contacts and contacts of contacts were being actively monitored. Six suspected, 13 probable and 35 confirmed EVD cases had been reported, and 25 (52%) of 48 probable and confirmed EVD cases had died.[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>]</p><p>This outbreak had several features that were worrisome for widespread transmission. Cases were reported over a 168-kilometer distance, including four confirmed cases in the ~1,200,000-inhabitant provincial capital of Equateur, Mbandaka, which is situated on the Congo River and bordering Congo-Brazzaville.[<xref rid="pone.0213190.ref002" ref-type="bibr">2</xref>] Moreover, travel to Kinshasa is frequent from Mbandaka. Given these risk factors, early epidemic growth profiles,[<xref rid="pone.0213190.ref004" ref-type="bibr">4</xref>] and evidence of unreported infection from previous outbreaks,[<xref rid="pone.0213190.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0213190.ref006" ref-type="bibr">6</xref>] the risk of a substantially larger outbreak could not be ignored.</p><p>The factors causing epidemic growth to peak have been debated. Delayed detection of EVD outbreaks and resulting widespread distributions of EVD have significantly contributed to epidemic growth.[<xref rid="pone.0213190.ref007" ref-type="bibr">7</xref>] In addition to traditional burial practices, Ebola treatment units with low quality care and/or high mortality rates have discouraged Ebola suspects from presenting to care and contribute to community-based transmission.[<xref rid="pone.0213190.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0213190.ref010" ref-type="bibr">10</xref>] Fragile, overwhelmed public health surveillance systems have also contributed to higher rates of unreported cases, who endanger urban communities,[<xref rid="pone.0213190.ref011" ref-type="bibr">11</xref>] which potentially have had higher transmission rates than rural communities.[<xref rid="pone.0213190.ref012" ref-type="bibr">12</xref>] Change to subcritical transmission (reproduction number below 1) tends to occur when Ebola response organizations deploy control, prevention and care measures,[<xref rid="pone.0213190.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0213190.ref014" ref-type="bibr">14</xref>] communities adopt more protective behaviors,[<xref rid="pone.0213190.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0213190.ref016" ref-type="bibr">16</xref>] and/or transmission decreases in a social network.[<xref rid="pone.0213190.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0213190.ref018" ref-type="bibr">18</xref>] Scientific advances with rapid diagnostics and vaccines from the West Africa outbreak were deployed in the April-July 2018 EVD outbreak in DRC and had the potential to limit Ebola virus transmission.[<xref rid="pone.0213190.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0213190.ref021" ref-type="bibr">21</xref>]</p><p>We used reported case counts during EVD outbreak in DRC and/or time series from 18 prior outbreaks to estimate the total outbreak size and duration with and without the use of vaccines. These projections were intended to help organizations anticipate and allocate sufficient resources for the duration of the April-July 2018 EVD outbreak.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Analysis</title><p>The following methods were used to generate projections: a stochastic branching process model,[<xref rid="pone.0213190.ref022" ref-type="bibr">22</xref>] statistical regression based on prior outbreaks, and Gott&#x02019;s Law.[<xref rid="pone.0213190.ref023" ref-type="bibr">23</xref>] On May 27, 54 EVD cases (6 suspected, 13 probable and 35 confirmed) were reported in three locations (Iboko, Bikoro, and Mbandaka) (<bold><xref ref-type="fig" rid="pone.0213190.g001">Fig 1</xref></bold>). Based on EVD situation reports from DRC, we assumed the ring vaccination program started the week of May 21, so we used May 23 as the time point that vaccines were implemented in the model at high and low coverage levels.</p><fig id="pone.0213190.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.g001</object-id><label>Fig 1</label><caption><title>Map of cases of Ebola virus disease per health zone in &#x000c9;quateur Province, Democratic Republic of Congo, as of May 27, 2018 (Source: Hansen/UMD/Google/USGS/NASA[<xref rid="pone.0213190.ref024" ref-type="bibr">24</xref>]).</title></caption><graphic xlink:href="pone.0213190.g001"/></fig></sec><sec id="sec004"><title>Data sources</title><p>Data on suspected, probable, and confirmed case counts were available from WHO situation reports in May 2018 and used as the basis for analysis. The published situation reports reflected data available up until May 11, 13, 16, 23, and 27, respectively. During the outbreak, the Ebola response team tested suspected cases for EVD and depending on positive or negative results, cases were classified as confirmed or not a case. The final outbreak case count was 54 probable and confirmed cases (no suspected cases).[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>] Due to this reporting process, probable and confirmed cases were used to parameterize the stochastic branching process model, regression models, and Gott&#x02019;s law. We added suspected cases to create an additional projection, using stochastic branching process model.</p></sec><sec id="sec005"><title>Stochastic branching process model</title><p>We modeled Ebola virus transmission using a stochastic branching process model, parameterized by transmission rates estimated from the dynamics of prior EVD outbreaks, and conditioned on agreement with reported case counts from the 2018 EVD outbreak to date. We incorporated high and low estimates of vaccination coverage into this model. Then we generated a set of probabilistic projections of the size and duration of simulated outbreaks in the current setting.</p><p>To estimate the reproduction number <italic>R</italic> as a function of the number of days from the beginning of the outbreak, we included reported cases by date from thirteen prior outbreaks and excluded the first historical outbreak reported in those countries (e.g., 1976 outbreak in Yambuko, DRC) (<bold><xref ref-type="supplementary-material" rid="pone.0213190.s001">S1 Table</xref></bold>).[<xref rid="pone.0213190.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0213190.ref032" ref-type="bibr">32</xref>] As there is a difference in the Ebola response system as well as community sensitization to EVD following a country&#x02019;s first outbreak, we employed this inclusion criterion to reflect the Ebola response system in DRC during what is now its ninth outbreak. The Wallinga-Teunis technique was used to estimate <italic>R</italic> for each case and therefore for each reporting date in the outbreak.[<xref rid="pone.0213190.ref033" ref-type="bibr">33</xref>]</p><p>The serial interval was defined as the interval between disease onset in an index case and disease onset in a person infected by that index case. The serial interval distribution used for this estimation was a gamma distribution with a mean of 14.5 days and a standard deviation of 5 days, with intervals rounded to the nearest whole number of days, consistent with the understanding that the serial interval of EVD cases ranges from 3 to 36 days with mean 14 to 15 days.[<xref rid="pone.0213190.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0213190.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pone.0213190.ref036" ref-type="bibr">36</xref>] Given that serial interval distribution, which we can denote as a probability <italic>w(t)</italic> of a <italic>t</italic>-day interval between given primary and secondary cases, Wallinga-Teunis estimation works by defining a relative likelihood <italic>p</italic><sub><italic>ij</italic></sub> for each possible source <italic>j</italic> of a given case <italic>i</italic>:
<disp-formula id="pone.0213190.e001"><alternatives><graphic xlink:href="pone.0213190.e001.jpg" id="pone.0213190.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>w</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi>t</mml:mi><mml:mi>j</mml:mi><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mi mathvariant="normal">&#x003a3;</mml:mi><mml:mi>k</mml:mi><mml:mspace width="0.25em"/><mml:mi>w</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi>t</mml:mi><mml:mi>k</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives></disp-formula>
and then deriving from that an estimated reproduction number <italic>Rj</italic> for each case:
<disp-formula id="pone.0213190.e002"><alternatives><graphic xlink:href="pone.0213190.e002.jpg" id="pone.0213190.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mi>R</mml:mi><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">&#x003a3;</mml:mi><mml:mi>i</mml:mi><mml:mspace width="0.25em"/><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mo>.</mml:mo></mml:math></alternatives></disp-formula></p><p>After using this technique to derive estimated reproduction numbers for each case in an outbreak, we use these estimated <italic>R</italic> values and cases&#x02019; onset dates <italic>d</italic> to estimate an initial reproduction number <italic>R</italic><sub><italic>0</italic></sub> and quenching rate &#x003c4; for each past outbreak by fitting an exponentially quenched curve:
<disp-formula id="pone.0213190.e003"><alternatives><graphic xlink:href="pone.0213190.e003.jpg" id="pone.0213190.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mi>o</mml:mi><mml:mspace width="0.25em"/><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003c4;</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></alternatives></disp-formula>
to each outbreak's <italic>R</italic> and <italic>d</italic> values (<bold><xref ref-type="supplementary-material" rid="pone.0213190.s002">S1 Fig</xref></bold>).</p><p>Transmission was modeled using a stochastic branching process model in which the number of secondary cases <italic>Si</italic> caused by any given primary case <italic>i</italic> was drawn from a negative binomial distribution whose mean is the reproduction number <italic>R</italic>:[<xref rid="pone.0213190.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0213190.ref038" ref-type="bibr">38</xref>]
<disp-formula id="pone.0213190.e004"><alternatives><graphic xlink:href="pone.0213190.e004.jpg" id="pone.0213190.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mo>&#x0223c;</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:math></alternatives></disp-formula>
where <italic>R</italic> is reproduction number as a function of day, <italic>k</italic> is a dispersion parameter, and Nb() denotes the negative binomial distribution. All transmission events were assumed to be independent. The serial interval between date of detection of each primary case and that of each of its secondary cases is assumed gamma distributed with mean 14.5 days and standard deviation 5 days, rounded to the nearest whole number of days, as above. The pair of parameters <italic>R</italic><sub><italic>0</italic></sub> and &#x003c4; estimated for the different past outbreaks used, and dispersion parameter <italic>k</italic>, were used in all possible combinations (with <italic>R</italic><sub><italic>0</italic></sub> and &#x003c4; taken as a unit) to simulate outbreaks.</p><p>This model generated randomly varying simulated outbreaks with a range of case counts per day. After the Ministry of Health and WHO conducted epidemiological investigations about the beginning of the EVD outbreak in &#x000c9;quateur Province, they concluded that the outbreak began on April 4, 2018, with a single case.[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>] The simulation process occurs as follows: proposed epidemic trajectories are generated in an initial step based on the above branching process, and these are then subsequently filtered by discarding all but those whose cumulative case counts match the known counts of the April-July 2018 EVD outbreak on known dates. The filtration accepts epidemics within a range of 3 cases more or less than each recorded value. This one-step particle filtering technique produced an ensemble of model outbreaks, filtered on agreement with the recorded trajectory of the outbreak to date. This filtered ensemble is then used to generate projections of the eventual outcome of the outbreak.[<xref rid="pone.0213190.ref012" ref-type="bibr">12</xref>]</p><p>To model vaccination coverage with respect to total transmission (unreported and reported), we multiplied the estimate of vaccine effectiveness by low and high estimates of reported cases. In a ring vaccination study at the end of the West Africa outbreak, the overall estimated rVSV-vectored vaccine efficacy was 100% and vaccine effectiveness was 64.6% in protecting all contacts and contacts of contacts from EVD in the randomized clusters, including unvaccinated cluster members.[<xref rid="pone.0213190.ref020" ref-type="bibr">20</xref>] Estimates of vaccine effectiveness were used in our stochastic model. The ring vaccination study found the vaccine to be effective against cases with onset dates 10 days or more from the date of vaccine administration, so we modeled the vaccination program as a proportionate reduction in the number of new cases with onsets 10 days or more after the program start date.</p><p>Then, past estimates of the proportion of unreported cases were used to estimate the proportion of exposed individuals not covered by the vaccination process. Based on a Sierra Leonean study from the 2013&#x02013;2016 outbreak,[<xref rid="pone.0213190.ref011" ref-type="bibr">11</xref>] we estimated that the percentage of reported cases in DRC would rise over time from a low of 68% to a high of 96%. Given these low and high estimates of reported cases and the estimate of vaccine effectiveness (64.6%), a low estimate of vaccination program coverage was 44% (68% multiplied by 64.6%) and a high estimate of vaccination program coverage was 62% (96% multiplied by 64.6%). The course of the outbreak with and without the vaccination program was modeled based on approximate dates available from situation reports.[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>]</p><p>For simulation based on probable and confirmed cases, from 122,683,392 simulated outbreaks, 21,036 were retained after filtering on approximate agreement with DRC case counts. For simulation based on probable, confirmed, and suspected cases, from 122,683,392 simulated outbreaks, 32,431 were retained after filtering. The simulated outbreaks that were retained after filtering were continued until they generated no further cases. This ensemble was used to derive a distribution of outbreak sizes and durations. Mean and median values and 95% prediction intervals were calculated using the 2.5 and 97.5 percentiles of simulated outbreak size and duration. These analyses were conducted using R 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec id="sec006"><title>Regression model</title><p>For contrast with the stochastic model above, a simple regression forecast was conducted based solely on outbreaks of size 10 or greater. Time series for all 18 such prior outbreaks were obtained, including seven prior ones from DRC, dating back to 1976 (<bold><xref ref-type="supplementary-material" rid="pone.0213190.s001">S1 Table</xref>; <xref ref-type="supplementary-material" rid="pone.0213190.s003">S2 Fig</xref></bold>).[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0213190.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0213190.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0213190.ref039" ref-type="bibr">39</xref>&#x02013;<xref rid="pone.0213190.ref045" ref-type="bibr">45</xref>] One (5.6%) of the 18 prior outbreaks in our sample (the 2013&#x02013;2016 West Africa outbreak) achieved a large size (over 28,000 cases). No exclusions were made; no attempt to model specific features of the April-July 2018 outbreak was conducted. The regression model predicted the outbreak size based on values of the outbreak size at a specific earlier time. The beginning of each outbreak was not reliably characterized; therefore, all time-series were aligned on the day they reached 10 cases. In the April-July 2018 outbreak, we observed cases over the period from April 4 to May 27 (day 0 to day 53). May 27 corresponded to day 34 since reaching 10 reported cases. For the prior 18 outbreaks, linear interpolation was used to obtain the number of cases on day 34 (after reaching 10 cases). To reduce the influence of outliers and high leverage points, and to improve linearity, we calculated the pseudologarithm transform f(x) = arcsinh(x/2), asymptotically logarithmic but well-behaved at 0. We used non-parametric Theil-Sen regression (R-package <italic>mblm</italic>) followed by calculation of the resulting prediction interval for a new observation.[<xref rid="pone.0213190.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0213190.ref047" ref-type="bibr">47</xref>] Finally, we reported the median and 95% central coverage intervals for the prediction distribution conditional on the value being no smaller than the observed value on day 34. Sensitivity analysis was conducted using ordinary least squares regression. These analyses were conducted using R 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec><sec id="sec007"><title>Gott&#x02019;s Law</title><p>Gott&#x02019;s Law was used to estimate the outbreak size using data through May 27 and May 11. We included a projection using data through May 11 because we hypothesized that this method performs better when the first situation report is posted than at later in the outbreak period.[<xref rid="pone.0213190.ref023" ref-type="bibr">23</xref>] Then we included a projection with the regression models using data through May 11 for comparison. With Gott&#x02019;s Law, we assume we have no special knowledge of our position on the epidemic curve. If we assume a non-informative uniform prior for the portion of the epidemic that still remains, the resulting probability distribution for the remaining number of cases <italic>y</italic> is:
<disp-formula id="pone.0213190.e005"><alternatives><graphic xlink:href="pone.0213190.e005.jpg" id="pone.0213190.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mi mathvariant="normal">P</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="normal">Y</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">y</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Y</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">y</mml:mi><mml:mn>2</mml:mn><mml:mo>.</mml:mo></mml:math></alternatives></disp-formula>
The median outbreak size was estimated, along with the two-sided 95% prediction interval.</p></sec><sec id="sec008"><title>Likelihood scoring</title><p>Each of the above models assigned a probability to any possible value of the total outbreak size. The final outbreak size was 54 probable and confirmed cases, so we identified the probability of this equivalent number (53) from each model, as of May 27. Probabilistic projections were scored using a log-likelihood (ignorance) score.[<xref rid="pone.0213190.ref048" ref-type="bibr">48</xref>]</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><p>As of May 27, 2018, there were 6 suspected, 13 probable and 35 confirmed EVD cases. Bikoko had ten confirmed cases, 11 probable cases, and one suspected case. Iboko had 21 confirmed cases, two probable cases, and one suspected case. Mbandaka had four confirmed cases and one suspected case (<bold><xref ref-type="fig" rid="pone.0213190.g001">Fig 1</xref></bold>).</p><p>With the stochastic model, we projected outbreak size and duration of probable and confirmed cases. In the absence of any vaccination program, the projected median outbreak size was 213.0 cases (mean 360.2; 95% prediction interval: 64.8, 1450.2). Median duration of projected outbreaks was 175.0 days (mean 182.8; 95% prediction interval: 86.0, 282.0). Using a lower estimate of 44% vaccination coverage, the median outbreak size was 104.0 cases (mean 118.8; 95% prediction interval: 58.0, 271.0) and median duration was 121.0 days (mean 124.6; 95% prediction interval: 74.0, 187.0). Using a higher estimate of 62% vaccination coverage, the median size was 82.0 EVD cases (mean 88.1; 95% prediction interval: 55.0, 156.0), and the median duration was 101.0 days (mean 103.4; 95% prediction interval: 68.0, 153.0). These projections with the stochastic model were repeated to estimate suspected, probable and confirmed cases <bold>(<xref rid="pone.0213190.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0213190.t002" ref-type="table">Table 2</xref>; Figs <xref ref-type="fig" rid="pone.0213190.g002">2</xref> &#x00026; <xref ref-type="fig" rid="pone.0213190.g003">3</xref>)</bold>.</p><fig id="pone.0213190.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.g002</object-id><label>Fig 2</label><caption><title>Cumulative case counts used in filtering stochastic branching process model.</title></caption><graphic xlink:href="pone.0213190.g002"/></fig><fig id="pone.0213190.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.g003</object-id><label>Fig 3</label><caption><title>Distribution of outbreak projections from stochastic branching process model.</title><p><bold>a.</bold> Mean and prediction interval of cumulative <bold>probable/confirmed</bold> case count by day in model projections, by proportion of vaccine coverage. Target case numbers and dates are marked with + signs; <bold>b.</bold> Mean and prediction interval of cumulative <bold>probable/confirmed/suspected</bold> case count by day in model projections, by proportion of vaccine coverage. Target case numbers and dates are marked with + signs; <bold>c.</bold> Mean and prediction interval of weekly average of per-day <bold>probable/confirmed</bold> case count in model projections; and <bold>d.</bold> Mean and prediction interval of weekly average of per-day <bold>probable/confirmed/suspected</bold> case count in model projections.</p></caption><graphic xlink:href="pone.0213190.g003"/></fig><table-wrap id="pone.0213190.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.t001</object-id><label>Table 1</label><caption><title>Distribution of projected outbreak size from stochastic branching process model.</title><p>Mean, median and 95% prediction interval of outbreak size, by proportion of vaccine coverage, using probable and confirmed cases with and without suspected cases.</p></caption><alternatives><graphic id="pone.0213190.t001g" xlink:href="pone.0213190.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Vaccine Coverage</th><th align="left" rowspan="1" colspan="1">Median Size</th><th align="left" rowspan="1" colspan="1">Mean Size</th><th align="left" rowspan="1" colspan="1">95% Prediction Interval</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">213.0</td><td align="left" rowspan="1" colspan="1">360.2</td><td align="left" rowspan="1" colspan="1">(64.8, 1450.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">104.0</td><td align="left" rowspan="1" colspan="1">118.8</td><td align="left" rowspan="1" colspan="1">(58.0, 271.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">82.0</td><td align="left" rowspan="1" colspan="1">88.1</td><td align="left" rowspan="1" colspan="1">(55.0, 156.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">63.0</td><td align="left" rowspan="1" colspan="1">108.9</td><td align="left" rowspan="1" colspan="1">(51.0, 450.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">62.0</td><td align="left" rowspan="1" colspan="1">74.0</td><td align="left" rowspan="1" colspan="1">(51.0, 153.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">61.0</td><td align="left" rowspan="1" colspan="1">66.8</td><td align="left" rowspan="1" colspan="1">(51.0, 111.9)</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0213190.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.t002</object-id><label>Table 2</label><caption><title>Distribution of projected outbreak duration from stochastic branching process model.</title><p>Mean, median and 95% prediction interval of outbreak duration, by proportion of vaccine coverage, using probable and confirmed cases with and without suspected cases.</p></caption><alternatives><graphic id="pone.0213190.t002g" xlink:href="pone.0213190.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Cases</th><th align="left" rowspan="1" colspan="1">Vaccine Coverage</th><th align="left" rowspan="1" colspan="1">Median Duration</th><th align="left" rowspan="1" colspan="1">Mean Duration</th><th align="left" rowspan="1" colspan="1">95% Prediction Interval</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">175.0</td><td align="left" rowspan="1" colspan="1">182.8</td><td align="left" rowspan="1" colspan="1">(86.0, 282.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">121.0</td><td align="left" rowspan="1" colspan="1">124.6</td><td align="left" rowspan="1" colspan="1">(74.0, 187.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Probable and confirmed</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">101.0</td><td align="left" rowspan="1" colspan="1">103.4</td><td align="left" rowspan="1" colspan="1">(68.0, 153.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">78.0</td><td align="left" rowspan="1" colspan="1">101.1</td><td align="left" rowspan="1" colspan="1">(51.0, 241.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">74.0</td><td align="left" rowspan="1" colspan="1">83.5</td><td align="left" rowspan="1" colspan="1">(51.0, 157.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">70.0</td><td align="left" rowspan="1" colspan="1">76.0</td><td align="left" rowspan="1" colspan="1">(51.0, 129.0)</td></tr></tbody></table></alternatives></table-wrap><p>With the regression based on past outbreaks, the median outbreak size was estimated to be 65.0 probable and confirmed cases (95% prediction interval: 48.8, 119.7), while use of ordinary least squares produced a median size of 97.9 probable and confirmed cases (95% prediction interval: 58.3, 169.9). Outbreak projections were also reported using data through May 11 in <bold><xref rid="pone.0213190.t003" ref-type="table">Table 3</xref></bold>.</p><table-wrap id="pone.0213190.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.t003</object-id><label>Table 3</label><caption><title>Distribution of outbreak projections from regression model.</title><p>Median and 95% prediction interval of outbreak size, by date from which cases are predicted, and by regression method, using probable and confirmed cases. Method 1: Theil-Sen regression with a pseudo-log transformation. Method 2: Ordinary Least Squares (OLS) Regression without transformation.</p></caption><alternatives><graphic id="pone.0213190.t003g" xlink:href="pone.0213190.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Using Data Through</th><th align="center" rowspan="1" colspan="1">Suspect Cases Included? (Y/N)</th><th align="center" rowspan="1" colspan="1">Total Outbreak Size: Median</th><th align="center" rowspan="1" colspan="1">95% Prediction Interval</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Theil-Sen</td><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">65.0</td><td align="center" rowspan="1" colspan="1">(48.8, 119.7)</td></tr><tr><td align="center" rowspan="1" colspan="1">OLS</td><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">97.9</td><td align="center" rowspan="1" colspan="1">(58.3, 169.9)</td></tr><tr><td align="center" rowspan="1" colspan="1">Theil-Sen</td><td align="center" rowspan="1" colspan="1">May 11</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">27.7</td><td align="center" rowspan="1" colspan="1">(20.3, 52.5)</td></tr><tr><td align="center" rowspan="1" colspan="1">OLS</td><td align="center" rowspan="1" colspan="1">May 11</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">50.1</td><td align="center" rowspan="1" colspan="1">(28.5, 89.0)</td></tr></tbody></table></alternatives></table-wrap><p>Gott&#x02019;s Law suggests that given 48 probable and confirmed cases, the median estimate of outbreak size was 96.0 cases (95% CI: 49.0, 1920.0). Using the 34 probable and confirmed cases as of May 11, the median estimate of outbreak size was 68.0 cases (95% CI: 35.0, 1360.0).</p><p>Of the mathematical models employed, the stochastic model that included suspected cases and high vaccination coverage had the best probabilistic score (log likelihood of -1.31). Likelihood scores of each model can be found in <bold><xref rid="pone.0213190.t004" ref-type="table">Table 4</xref></bold>.</p><table-wrap id="pone.0213190.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0213190.t004</object-id><label>Table 4</label><caption><title>Probabilistic scoring for stochastic branching process model, regression models and Gott&#x02019;s Law.</title><p>Date of prediction, vaccine coverage, inclusion of suspected cases and log-likelihood. For the regression model: Method 1&#x02014;Theil Sen regression with a pseudo-log transformation. Method 2&#x02014;OLS Linear Regression without transformation. Our mathematical models were scored against the actual outbreak size of 54 EVD cases. Note: &#x0201c;-&#x0201d;indicates that the model did not include vaccine coverage.</p></caption><alternatives><graphic id="pone.0213190.t004g" xlink:href="pone.0213190.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Using Data Through</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Vaccine Coverage</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Suspect Cases Included? (Y/N)</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1">Log Likelihood</th></tr></thead><tbody><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"><bold>Stochastic</bold></td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">Y</td><td align="center" rowspan="1" colspan="1">-1.98</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">Y</td><td align="center" rowspan="1" colspan="1">-1.50</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">Y</td><td align="center" rowspan="1" colspan="1">-1.31</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-2.92</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-2.53</td></tr><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">May 27</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">0.62</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">N</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">-2.27</td></tr><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"><bold>Regression</bold></td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Theil-Sen</td><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-3.47</td></tr><tr><td align="center" rowspan="1" colspan="1">Linear</td><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-6.07</td></tr><tr><td align="center" rowspan="1" colspan="1">Theil-Sen</td><td align="center" rowspan="1" colspan="1">May 11</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-5.92</td></tr><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">Linear</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">May 11</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">-</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">N</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">-3.62</td></tr><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"><bold>Gott&#x02019;s Law</bold></td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">May 27</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">-4.07</td></tr><tr><td align="center" style="border-bottom:thick" rowspan="1" colspan="1"/><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">May 11</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">-</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">N</td><td align="center" style="border-bottom:thick" rowspan="1" colspan="1">-4.97</td></tr></tbody></table></alternatives></table-wrap></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>When we were conducting our projections in late May, this outbreak still had the potential to become the largest outbreak in DRC since 2007. Vaccine use, regardless of coverage levels, was projected to prevent more than half of the total outbreak size. Vaccines, however, were only part of concurrent prevention, control, and care strategies.[<xref rid="pone.0213190.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0213190.ref049" ref-type="bibr">49</xref>&#x02013;<xref rid="pone.0213190.ref051" ref-type="bibr">51</xref>] We also found that the stochastic model with vaccine use projected that rare, large outbreaks (tail of the distribution of the model without vaccinations) were prevented, suggesting that repeat epidemics such as the 2013&#x02013;2016 West African outbreak may have been highly unlikely once vaccines were rolled out.</p><p>Multiple models were used to estimate total outbreak size. This study exemplified how mathematical models, including simple regressions, can be useful for advising real-time decision making because they provided rapid projections and similar estimates of <italic>R</italic> as compared to complex models,[<xref rid="pone.0213190.ref035" ref-type="bibr">35</xref>] even though real-time modeling projections historically overestimated outbreak size and duration.[<xref rid="pone.0213190.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0213190.ref053" ref-type="bibr">53</xref>] Our projections that included suspected cases did not suggest that vaccines had as much of an impact as our model using only probable and confirmed cases. The trends associated with suspected cases were subject to several factors, including operational choices of response teams and maturity of the outbreak. Nevertheless, suspected case counts may at times provide a better glimpse into the near future of an outbreak than the confirmed and probable case counts. In our case, use of the time series of confirmed, probable, and suspect cases yielded a forecast closer to the final outbreak size. However, as model projections can be highly sensitive to inclusion of suspected cases and use of exact case counts, particularly the last few counts in the available data, conclusions must be taken with caution.</p><p>Thus far, there had been a strong local and international response, and deployment of vaccines and rapid diagnostic tests (RDT) occurred early in response efforts.[<xref rid="pone.0213190.ref001" ref-type="bibr">1</xref>] RDTs were being used to screen Ebola suspects while the vaccines are being administered to high-risk groups for EVD, including healthcare workers, contacts, and contacts of contacts. To further limit epidemic growth from unreported cases, particularly those who have non-specific symptoms but are screened negative by the WHO case definition, more decentralized use of RDTs should be considered. In addition, formal evaluations of vaccine use and coverage on transmission reduction are needed.</p><p>There are limitations to our projections. Projection distributions were right-skewed, with long tails (and we therefore reported the median instead of the mean). While there have been 22 observed EVD outbreaks with a case count greater than ten cases, we were unable to include all prior outbreaks in our estimates due to data availability.[<xref rid="pone.0213190.ref045" ref-type="bibr">45</xref>,<xref rid="pone.0213190.ref054" ref-type="bibr">54</xref>] Note that the simple regression projection is based entirely on past outbreaks of EVD (measured and reported in different ways), and cannot account for the improved control measures and vaccination in the way that a mechanistic model does. We included, however, as much real-time information into our estimates as possible, but situations such as the introduction of EVD into a large urban population and implementation of RDTs and vaccines are new to DRC. We did not include vaccination of healthcare workers in the stochastic model. Our estimates of vaccination effectiveness and reported cases were obtained from West Africa because these estimates were not available for the EVD outbreak in &#x000c9;quateur. These modeling assumptions may not have been consistent with estimates in DRC and should be carefully considered prior to use in other EVD outbreaks.</p><p>A strength of our approach was the use of multiple methods to estimate the outbreak size, although we note that Gott&#x02019;s Law has not been validated for outbreak projections in other EVD outbreaks. Additional limitations of the models were that they did not include parameters to address spatial spread, urban settings, conflict zone, or other factors that may have influenced the accuracy of the predictions, particularly in the 2018&#x02013;2019 EVD outbreak in Northeastern DRC (ongoing in January 2019). While it can also be useful and achievable to use models of these kinds to make short-term forecasts for evaluation of model performance and to inform outbreak response,[<xref rid="pone.0213190.ref055" ref-type="bibr">55</xref>] the present study was limited to projections of final outbreak size and duration.</p><p>Among our three mathematical models, the model that performed the best (stochastic model with suspected cases and high vaccine coverage) predicted total outbreak sizes close to the true outcome. When EVD cases were introduced into Mbandaka, there was concern that the total outbreak size could exceed most prior EVD outbreaks in DRC. Indeed, our projections were consistent with this concern because models without vaccine coverage projected higher total outbreak sizes. In our stochastic model projections, vaccine use reduced mean total outbreak size by more than half, regardless of coverage levels (<italic>p</italic>&#x0003c;0.001, Welch&#x02019;s <italic>t</italic>-test). As vaccine coverage was scaled up, an influx of support was warranted to support and bolster the evolving rapid response; however, continued efforts to strengthen the health system are equally as warranted so that we can respond to future outbreaks before they become epidemics. Relatively simple mathematical models updated in real time may inform outbreak response teams with projections of total outbreak size and duration.</p></sec><sec sec-type="supplementary-material" id="sec011"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0213190.s001"><label>S1 Table</label><caption><title>List of 21 prior Ebola outbreaks from 1976 to 2016 by time period, country, confirmed/probable reported and time series case count, outbreak inclusion into the regression and stochastic models.</title><p>(DOCX)</p></caption><media xlink:href="pone.0213190.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0213190.s002"><label>S1 Fig</label><caption><title>Estimates of temporal change in reproduction number <italic>R</italic> in thirteen past Ebola outbreaks.</title><p>To each series of <italic>R</italic> estimates we fit an exponentially decaying curve, to be used in our simulations.</p><p>(TIFF)</p></caption><media xlink:href="pone.0213190.s002.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0213190.s003"><label>S2 Fig</label><caption><title>Time-series of 18 prior Ebola outbreaks from 1976 to 2016 was depicted.</title><p>(TIFF)</p></caption><media xlink:href="pone.0213190.s003.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the Ebola responders for their efforts in the 2018 EVD outbreak in &#x000c9;quateur, Democratic Republic of Congo.</p></ack><ref-list><title>References</title><ref id="pone.0213190.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization Regional Office for Africa. Health topics: Ebola virus disease. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.afro.who.int/health-topics/ebola-virus-disease">http://www.afro.who.int/health-topics/ebola-virus-disease</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref002"><label>2</label><mixed-citation publication-type="other">World Health Organization. Emergencies preparedness, response. 14 May 2018. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/14-may-2018-ebola-drc/en/">http://www.who.int/csr/don/14-may-2018-ebola-drc/en/</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Branswell</surname><given-names>H</given-names></name>. <article-title>Excitement over use of Ebola vaccine in outbreak tempered by real-world challenges</article-title>. <source>Stat. Health</source>. <day>23</day>
<month>5</month>
<year>2018</year> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.statnews.com/2018/05/23/ebola-vaccine-drc-real-world-challenges/">https://www.statnews.com/2018/05/23/ebola-vaccine-drc-real-world-challenges/</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Chowell</surname><given-names>G</given-names></name>, <name><surname>Sattenspiel</surname><given-names>L</given-names></name>, <name><surname>Bansal</surname><given-names>S</given-names></name>, <name><surname>Viboud</surname><given-names>C</given-names></name>. <article-title>Mathematical models to characterize early epidemic growth: A review</article-title>. <source><italic toggle="yes">Phys Life Rev</italic></source>
<year>2016</year>; <volume>18</volume>: <fpage>66</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.plrev.2016.07.005</pub-id>
<?supplied-pmid 27451336?><pub-id pub-id-type="pmid">27451336</pub-id></mixed-citation></ref><ref id="pone.0213190.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Barrie</surname><given-names>MB</given-names></name>, <name><surname>Mesman</surname><given-names>AW</given-names></name>, <name><surname>Karku</surname><given-names>S</given-names></name>, <name><surname>Quiwa</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Minimally symptomatic infection in an Ebola 'hotspot': a cross-sectional serosurvey</article-title>. <source><italic toggle="yes">PLoS Negl Trop Dis</italic></source>
<year>2016</year>; <volume>10</volume>(<issue>11</issue>): <fpage>e0005087</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0005087</pub-id>
<?supplied-pmid 27846221?><pub-id pub-id-type="pmid">27846221</pub-id></mixed-citation></ref><ref id="pone.0213190.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Barrie</surname><given-names>MB</given-names></name>, <name><surname>Mesman</surname><given-names>AW</given-names></name>, <etal>et al</etal>
<article-title>Anatomy of a hotspot: chain and seroepidemiology of Ebola virus transmission, Sukudu, Sierra Leone, 2015&#x02013;16</article-title>. <source><italic toggle="yes">J Infect Dis</italic></source>
<year>2018</year>.</mixed-citation></ref><ref id="pone.0213190.ref007"><label>7</label><mixed-citation publication-type="journal"><collab>WHO Ebola Response Team</collab>. <article-title>After Ebola in West Africa&#x02014;Unpredictable Risks, Preventable Epidemics</article-title>. <source>N Engl J Med</source>
<year>2016</year>;<volume>375</volume>:<fpage>587</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMsr1513109</pub-id>
<?supplied-pmid 27509108?><pub-id pub-id-type="pmid">27509108</pub-id></mixed-citation></ref><ref id="pone.0213190.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Barrie</surname><given-names>MB</given-names></name>, <name><surname>Nutt</surname><given-names>CT</given-names></name>, <etal>et al</etal>
<article-title>The Ebola suspect's dilemma</article-title>. <source><italic toggle="yes">Lancet Glob Health</italic></source>
<year>2017</year>; <volume>5</volume>(<issue>3</issue>): <fpage>e254</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(17)30041-4</pub-id>
<?supplied-pmid 28193386?><pub-id pub-id-type="pmid">28193386</pub-id></mixed-citation></ref><ref id="pone.0213190.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Barrie</surname><given-names>MB</given-names></name>, <name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Dibba</surname><given-names>Y</given-names></name>, <name><surname>Koedoyoma</surname><given-names>S</given-names></name>, <name><surname>Farmer</surname><given-names>PE</given-names></name>. <article-title>Biosocial Approaches to the 2013&#x02013;2016 Ebola Pandemic</article-title>. <source><italic toggle="yes">Health Hum Rights</italic> 2016</source>; <volume>18</volume>(<issue>1</issue>): <fpage>115</fpage>&#x02013;<lpage>28</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Chertow</surname><given-names>DS</given-names></name>, <name><surname>Kleine</surname><given-names>C</given-names></name>, <name><surname>Edwards</surname><given-names>JK</given-names></name>, <name><surname>Scaini</surname><given-names>R</given-names></name>, <name><surname>Giuliani</surname><given-names>R</given-names></name>, <name><surname>Sprecher</surname><given-names>A</given-names></name>. <article-title>Ebola virus disease in West Africa&#x02014;clinical manifestations and management</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>
<year>2014</year>; <volume>371</volume>(<issue>22</issue>): <fpage>2054</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1413084</pub-id>
<?supplied-pmid 25372854?><pub-id pub-id-type="pmid">25372854</pub-id></mixed-citation></ref><ref id="pone.0213190.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Dalziel</surname><given-names>BD</given-names></name>, <name><surname>Lau</surname><given-names>MSY</given-names></name>, <name><surname>Tiffany</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Unreported cases in the 2014&#x02013;2016 Ebola epidemic: Spatiotemporal variation, and implications for estimating transmission</article-title>. <source><italic toggle="yes">PLoS Negl Trop Dis</italic> 2018</source>; <volume>12</volume>(<issue>1</issue>): <fpage>e0006161</fpage>.</mixed-citation></ref><ref id="pone.0213190.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Krauer</surname><given-names>F</given-names></name>, <name><surname>Gsteiger</surname><given-names>S</given-names></name>, <name><surname>Low</surname><given-names>N</given-names></name>, <name><surname>Hansen</surname><given-names>CH</given-names></name>, <name><surname>Althaus</surname><given-names>CL</given-names></name>. <article-title>Heterogeneity in District-Level Transmission of Ebola Virus Disease during the 2013&#x02013;2015 Epidemic in West Africa</article-title>. <source><italic toggle="yes">PLoS Negl Trop Dis</italic> 2016</source>; <volume>10</volume>(<issue>7</issue>): <fpage>e0004867</fpage>.</mixed-citation></ref><ref id="pone.0213190.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Funk</surname><given-names>S</given-names></name>, <name><surname>Ciglenecki</surname><given-names>I</given-names></name>, <name><surname>Tiffany</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>The impact of control strategies and behavioural changes on the elimination of Ebola from Lofa County, Liberia</article-title>. <source><italic toggle="yes">Philos Trans R Soc Lond B Biol Sci</italic></source>
<year>2017</year>; <volume>372</volume>(<issue>1721</issue>).</mixed-citation></ref><ref id="pone.0213190.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Lewnard</surname><given-names>JA</given-names></name>, <name><surname>Ndeffo Mbah</surname><given-names>ML</given-names></name>, <name><surname>Alfaro-Murillo</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis</article-title>. <source>Lancet Infect Dis</source>
<year>2014</year>; <volume>14</volume>(<issue>12</issue>): <fpage>1189</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70995-8</pub-id>
<?supplied-pmid 25455986?><pub-id pub-id-type="pmid">25455986</pub-id></mixed-citation></ref><ref id="pone.0213190.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Winters</surname><given-names>M</given-names></name>, <name><surname>Jalloh</surname><given-names>MF</given-names></name>, <name><surname>Sengeh</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Risk Communication and Ebola-Specific Knowledge and Behavior during 2014&#x02013;2015 Outbreak, Sierra Leone</article-title>. <source><italic toggle="yes">Emerg Infect Dis</italic></source> 2018; <volume>24</volume>(<issue>2</issue>): <fpage>336</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.3201/eid2402.171028</pub-id>
<?supplied-pmid 29350151?><pub-id pub-id-type="pmid">29350151</pub-id></mixed-citation></ref><ref id="pone.0213190.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Figueroa</surname><given-names>ME</given-names></name>. <article-title>A Theory-Based Socioecological Model of Communication and Behavior for the Containment of the Ebola Epidemic in Liberia</article-title>. <source>J Health Commun</source>
<year>2017</year>; <volume>22</volume>(<issue>sup1</issue>): <fpage>5</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/10810730.2016.1231725</pub-id>
<?supplied-pmid 28854136?><pub-id pub-id-type="pmid">28854136</pub-id></mixed-citation></ref><ref id="pone.0213190.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kiskowski</surname><given-names>M</given-names></name>, <name><surname>Chowell</surname><given-names>G</given-names></name>. <article-title>Modeling household and community transmission of Ebola virus disease: Epidemic growth, spatial dynamics and insights for epidemic control</article-title>. <source>Virulence</source>
<year>2016</year>; <volume>7</volume>(<issue>2</issue>): <fpage>163</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1080/21505594.2015.1076613</pub-id>
<?supplied-pmid 26399855?><pub-id pub-id-type="pmid">26399855</pub-id></mixed-citation></ref><ref id="pone.0213190.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Bellan</surname><given-names>SE</given-names></name>, <name><surname>Pulliam</surname><given-names>JR</given-names></name>, <name><surname>Dushoff</surname><given-names>J</given-names></name>, <name><surname>Meyers</surname><given-names>LA</given-names></name>. <article-title>Ebola control: effect of asymptomatic infection and acquired immunity</article-title>. <source><italic toggle="yes">Lancet</italic></source>
<year>2014</year>; <volume>384</volume>(<issue>9953</issue>): <fpage>1499</fpage>&#x02013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61839-0</pub-id>
<?supplied-pmid 25390569?><pub-id pub-id-type="pmid">25390569</pub-id></mixed-citation></ref><ref id="pone.0213190.ref019"><label>19</label><mixed-citation publication-type="other">FDA. OraQuick Rapid Antigen Test for Ebola. For Use Under Emergency Use Authorization (EUA) Only. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM456912.pdf">http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM456912.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name>, <name><surname>Camacho</surname><given-names>A</given-names></name>, <name><surname>Longini</surname><given-names>IM</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola &#x000c7;a Suffit!)</article-title>. <source><italic toggle="yes">Lancet</italic></source>
<year>2017</year>; <volume>389</volume>(<issue>10068</issue>): <fpage>505</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32621-6</pub-id>
<?supplied-pmid 28017403?><pub-id pub-id-type="pmid">28017403</pub-id></mixed-citation></ref><ref id="pone.0213190.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Dhillon</surname><given-names>RS</given-names></name>, <name><surname>Srikrishna</surname><given-names>D</given-names></name>, <name><surname>Garry</surname><given-names>RF</given-names></name>, <name><surname>Chowell</surname><given-names>G</given-names></name>. <article-title>Ebola control: rapid diagnostic testing</article-title>. <source><italic toggle="yes">Lancet Infect Dis</italic></source>
<year>2015</year>; <volume>15</volume>(<issue>2</issue>): <fpage>147</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Galton</surname><given-names>F</given-names></name>, <name><surname>Watson</surname><given-names>HW</given-names></name>. <article-title>On the probability of the extinction of families</article-title>. <source>J Royal Anthropol Inst</source>
<year>1875</year>
<volume>4</volume>; <fpage>138</fpage>&#x02013;<lpage>144</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Gott</surname><given-names>JR</given-names></name>. <article-title>Implications of the Copernican principle for our future prospects</article-title>. <source>Nature</source>
<year>1993</year>
<volume>363</volume>; <fpage>315</fpage>&#x02013;<lpage>319</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>MC</given-names></name>, <name><surname>Potapov</surname><given-names>PV</given-names></name>, <name><surname>Moore</surname><given-names>R</given-names></name>, <name><surname>Hancher</surname><given-names>M</given-names></name>, <name><surname>Turubanova</surname><given-names>SA</given-names></name>, <name><surname>Tyukavina</surname><given-names>A</given-names></name>, <name><surname>Thau</surname><given-names>D</given-names></name>, <name><surname>Stehman</surname><given-names>SV</given-names></name>, <name><surname>Goetz</surname><given-names>SJ</given-names></name>, <name><surname>Loveland</surname><given-names>TR</given-names></name>, <name><surname>Kommareddy</surname><given-names>A</given-names></name>, <name><surname>Egorov</surname><given-names>A</given-names></name>, <name><surname>Chini</surname><given-names>L</given-names></name>, <name><surname>Justice</surname><given-names>CO</given-names></name>, <name><surname>Townshend</surname><given-names>JRG</given-names></name>. <article-title>High-Resolution Global Maps of 21st-Century Forest Cover Change</article-title>. <source>Science</source>
<year>2013</year>; <volume>42</volume>(<issue>15</issue>): <fpage>850</fpage>&#x02013;<lpage>53</lpage>. Data available on-line from: <ext-link ext-link-type="uri" xlink:href="http://earthenginepartners.appspot.com/science-2013-global-forest">http://earthenginepartners.appspot.com/science-2013-global-forest</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref025"><label>25</label><mixed-citation publication-type="journal"><article-title>Ebola haemorrhagic fever in Sudan, 1976</article-title>. <collab>Report of a WHO/International Study Team</collab>. <source><italic toggle="yes">Bull World Health Organ</italic></source>
<year>1978</year>; <volume>56</volume>(<issue>2</issue>): <fpage>247</fpage>&#x02013;<lpage>70</lpage>. <?supplied-pmid 307455?><pub-id pub-id-type="pmid">307455</pub-id></mixed-citation></ref><ref id="pone.0213190.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Baron</surname><given-names>RC</given-names></name>, <name><surname>McCormick</surname><given-names>JB</given-names></name>, <name><surname>Zubeir</surname><given-names>OA</given-names></name>. <article-title>Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread</article-title>. <source><italic toggle="yes">Bull World Health Organ</italic></source>
<year>1983</year>; <volume>61</volume>(<issue>6</issue>): <fpage>997</fpage>&#x02013;<lpage>1003</lpage>. <?supplied-pmid 6370486?><pub-id pub-id-type="pmid">6370486</pub-id></mixed-citation></ref><ref id="pone.0213190.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Georges</surname><given-names>AJ</given-names></name>, <name><surname>Leroy</surname><given-names>EM</given-names></name>, <name><surname>Renaut</surname><given-names>AA</given-names></name>, <etal>et al</etal>
<article-title>Ebola hemorrhagic fever outbreaks in Gabon, 1994&#x02013;1997: epidemiologic and health control issues</article-title>. <source><italic toggle="yes">J Infect Dis</italic></source>
<year>1999</year>; <volume>179</volume>
<issue>Suppl 1</issue>: <fpage>S65</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">9988167</pub-id></mixed-citation></ref><ref id="pone.0213190.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>AS</given-names></name>, <name><surname>Tshioko</surname><given-names>FK</given-names></name>, <name><surname>Heymann</surname><given-names>DL</given-names></name>, <etal>et al</etal>
<article-title>The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995</article-title>. <article-title>Commission de Lutte contre les Epid&#x000e9;mies &#x000e0; Kikwit</article-title>. <source><italic toggle="yes">J Infect Dis</italic></source>
<year>1999</year>; <volume>179</volume>
<issue>Suppl 1</issue>: <fpage>S76</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref029"><label>29</label><mixed-citation publication-type="other">Boumandouki P, Formenty P, Alain E, et al. Prise en charge des malades et des d&#x000e9;funts lors de l'&#x000e9;pid&#x000e9;mie de fi&#x000e8;vre h&#x000e9;morragique due au virus Ebola d'octobre &#x000e0; d&#x000e9;cembre 2003. 2005. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/280954258_Prise_en_charge_des_malades_et_des_defunts_lors_de_l%27epidemie_de_fievre_hemorragique_due_au_virus_Ebola_d%27octobre_a_decembre_2003">https://www.researchgate.net/publication/280954258_Prise_en_charge_des_malades_et_des_defunts_lors_de_l%27epidemie_de_fievre_hemorragique_due_au_virus_Ebola_d%27octobre_a_decembre_2003</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Nkoghe</surname><given-names>D</given-names></name>, <name><surname>Kone</surname><given-names>ML</given-names></name>, <name><surname>Yada</surname><given-names>A</given-names></name>, <name><surname>Leroy</surname><given-names>E</given-names></name>. <article-title>A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005</article-title>. <source><italic toggle="yes">Trans R Soc Trop Med Hyg</italic></source>
<year>2011</year>; <volume>105</volume>(<issue>8</issue>): <fpage>466</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.trstmh.2011.04.011</pub-id>
<?supplied-pmid 21605882?><pub-id pub-id-type="pmid">21605882</pub-id></mixed-citation></ref><ref id="pone.0213190.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Maganga</surname><given-names>GD</given-names></name>, <name><surname>Kapetshi</surname><given-names>J</given-names></name>, <name><surname>Berthet</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Ebola virus disease in the Democratic Republic of Congo</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>
<year>2014</year>; <volume>371</volume>(<issue>22</issue>): <fpage>2083</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1411099</pub-id>
<?supplied-pmid 25317743?><pub-id pub-id-type="pmid">25317743</pub-id></mixed-citation></ref><ref id="pone.0213190.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>MacNeil</surname><given-names>A</given-names></name>, <name><surname>Farnon</surname><given-names>EC</given-names></name>, <name><surname>Morgan</surname><given-names>OW</given-names></name>, <etal>et al</etal>
<article-title>Filovirus outbreak detection and surveillance: lessons from Bundibugyo</article-title>. <source><italic toggle="yes">J Infect Dis</italic></source>
<year>2011</year>; <volume>204</volume>
<issue>Suppl 3</issue>: <fpage>S761</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21987748</pub-id></mixed-citation></ref><ref id="pone.0213190.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Wallinga</surname><given-names>J</given-names></name>, <name><surname>Teunis</surname><given-names>P</given-names></name>. <article-title>Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures</article-title>. <source><italic toggle="yes">Am J Epidemiol</italic></source>
<year>2004</year>; <volume>160</volume>(<issue>6</issue>): <fpage>509</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwh255</pub-id>
<?supplied-pmid 15353409?><pub-id pub-id-type="pmid">15353409</pub-id></mixed-citation></ref><ref id="pone.0213190.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Aylward</surname><given-names>B</given-names></name>, <name><surname>Barboza</surname><given-names>P</given-names></name>, <name><surname>Bawo</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Ebola virus disease in West Africa&#x02014;the first 9 months of the epidemic and forward projections</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>
<year>2014</year>; <volume>371</volume>(<issue>16</issue>): <fpage>1481</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1411100</pub-id>
<?supplied-pmid 25244186?><pub-id pub-id-type="pmid">25244186</pub-id></mixed-citation></ref><ref id="pone.0213190.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>ZS</given-names></name>, <name><surname>Bui</surname><given-names>CM</given-names></name>, <name><surname>Chughtai</surname><given-names>AA</given-names></name>, <name><surname>Macintyre</surname><given-names>CR</given-names></name>. <article-title>A systematic review of early modelling studies of Ebola virus disease in West Africa</article-title>. <source><italic toggle="yes">Epidemiol Infect</italic></source>
<year>2017</year>; <volume>145</volume>(<issue>6</issue>): <fpage>1069</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268817000164</pub-id>
<?supplied-pmid 28166851?><pub-id pub-id-type="pmid">28166851</pub-id></mixed-citation></ref><ref id="pone.0213190.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Chowell</surname><given-names>G</given-names></name>, <name><surname>Nishiura</surname><given-names>H</given-names></name>. <article-title>Transmission dynamics and control of Ebola virus disease (EVD): a review</article-title>. <source>BMC Med</source>
<year>2014</year>; <volume>12</volume>: <fpage>196</fpage>
<pub-id pub-id-type="doi">10.1186/s12916-014-0196-0</pub-id>
<?supplied-pmid 25300956?><pub-id pub-id-type="pmid">25300956</pub-id></mixed-citation></ref><ref id="pone.0213190.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Blumberg</surname><given-names>S</given-names></name>, <name><surname>Lloyd-Smith</surname><given-names>JO</given-names></name>. <article-title>Comparing methods for estimating R0 from the size distribution of subcritical transmission chains</article-title>. <source>Epidemics</source>
<year>2013</year>; <volume>5</volume>(<issue>3</issue>): <fpage>131</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.epidem.2013.05.002</pub-id>
<?supplied-pmid 24021520?><pub-id pub-id-type="pmid">24021520</pub-id></mixed-citation></ref><ref id="pone.0213190.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Lloyd-Smith</surname><given-names>JO</given-names></name>, <name><surname>Schreiber</surname><given-names>SJ</given-names></name>, <name><surname>Kopp</surname><given-names>PE</given-names></name>, <name><surname>Getz</surname><given-names>WM</given-names></name>. <article-title>Superspreading and the effect of individual variation on disease emergence</article-title>. <source><italic toggle="yes">Nature</italic></source>
<year>2005</year>; <volume>438</volume>(<issue>7066</issue>): <fpage>355</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature04153</pub-id>
<?supplied-pmid 16292310?><pub-id pub-id-type="pmid">16292310</pub-id></mixed-citation></ref><ref id="pone.0213190.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Rosello</surname><given-names>A</given-names></name>, <name><surname>Mossoko</surname><given-names>M</given-names></name>, <name><surname>Flasche</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Ebola virus disease in the Democratic Republic of the Congo, 1976&#x02013;2014</article-title>. <source>Elife</source>
<year>2015</year>; <volume>4</volume>.</mixed-citation></ref><ref id="pone.0213190.ref040"><label>40</label><mixed-citation publication-type="journal"><article-title>Outbreak(s) of Ebola haemorrhagic fever, Congo and Gabon, October 2001-July 2002</article-title>. <source>Wkly Epidemiol Rec</source>
<year>2003</year>; <volume>78</volume>(<issue>26</issue>): <fpage>223</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 15571171?><pub-id pub-id-type="pmid">15571171</pub-id></mixed-citation></ref><ref id="pone.0213190.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Camacho</surname><given-names>A</given-names></name>, <name><surname>Kucharski</surname><given-names>AJ</given-names></name>, <name><surname>Funk</surname><given-names>S</given-names></name>, <name><surname>Breman</surname><given-names>J</given-names></name>, <name><surname>Piot</surname><given-names>P</given-names></name>, <name><surname>Edmunds</surname><given-names>WJ</given-names></name>. <article-title>Potential for large outbreaks of Ebola virus disease</article-title>. Epidemics <year>2014</year>; <volume>9</volume>: <fpage>70</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.epidem.2014.09.003</pub-id>
<?supplied-pmid 25480136?><pub-id pub-id-type="pmid">25480136</pub-id></mixed-citation></ref><ref id="pone.0213190.ref042"><label>42</label><mixed-citation publication-type="other">World Health Organization. Weekly epidemiological record. Abonnement annuel. 2005. (43)80;369&#x02013;376. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/wer/2005/wer8043.pdf">http://www.who.int/wer/2005/wer8043.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref043"><label>43</label><mixed-citation publication-type="other">Okware SI. Three ebola outbreaks in Uganda 2000&#x02013;2011. University of Bergen dissertation for PhD. 2015. Available at: <ext-link ext-link-type="uri" xlink:href="http://bora.uib.no/handle/1956/9239">http://bora.uib.no/handle/1956/9239</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Althaus</surname><given-names>CL</given-names></name>, <name><surname>Low</surname><given-names>N</given-names></name>, <name><surname>Musa</surname><given-names>EO</given-names></name>, <name><surname>Shuaib</surname><given-names>F</given-names></name>, <name><surname>Gsteiger</surname><given-names>S</given-names></name>. <article-title>Ebola virus disease outbreak in Nigeria: Transmission dynamics and rapid control</article-title>. <source>Epidemics</source>
<year>2015</year>; <volume>11</volume>: <fpage>80</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.epidem.2015.03.001</pub-id>
<?supplied-pmid 25979285?><pub-id pub-id-type="pmid">25979285</pub-id></mixed-citation></ref><ref id="pone.0213190.ref045"><label>45</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease): History of Ebola Virus Disease: 2014&#x02013;2016 Ebola Outbreak in West Africa: Case Counts. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/case-counts.html">https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/case-counts.html</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Sen</surname><given-names>PK</given-names></name>. <article-title>Estimates of the regression coefficient based on Kendall's tau</article-title>. <source>Journal of the American Statistical Association</source>, <year>1968</year>
<volume>63</volume>(<issue>324</issue>);<fpage>1379</fpage>&#x02013;<lpage>1389</lpage>.</mixed-citation></ref><ref id="pone.0213190.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Theil</surname><given-names>H</given-names></name>. <article-title>A rank-invariant method of linear and polynomial regression analysis. I, II, III</article-title>. <source>Nederl Akad Wetensch, Proc</source>, <year>1950</year>
<volume>53</volume>;<fpage>386</fpage>&#x02013;<lpage>392</lpage>,521&#x02013;525,1397&#x02013;1412. MR0036489.</mixed-citation></ref><ref id="pone.0213190.ref048"><label>48</label><mixed-citation publication-type="other">Brocker J, Smith LA. Scoring probabilistic forecasts: the importance of being proper. American Meterological Society. 4 November 2005. Available at: <pub-id pub-id-type="doi">10.1175/WAF966.1</pub-id>.</mixed-citation></ref><ref id="pone.0213190.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Mukadi</surname><given-names>P</given-names></name>, <name><surname>Dhillon</surname><given-names>RS</given-names></name>. <article-title>Beyond vaccines: improving survival rates in the DRC Ebola outbreak</article-title>. <source><italic toggle="yes">Lancet</italic></source>
<year>2018</year>.</mixed-citation></ref><ref id="pone.0213190.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Drasher</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Food Insecurity as a Risk Factor for Outcomes Related to Ebola Virus Disease in Kono District, Sierra Leone: A Cross-Sectional Study</article-title>. <source><italic toggle="yes">Am J Trop Med Hyg</italic></source>
<year>2018</year>; <volume>98</volume>(<issue>5</issue>): <fpage>1484</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.17-0820</pub-id>
<?supplied-pmid 29557329?><pub-id pub-id-type="pmid">29557329</pub-id></mixed-citation></ref><ref id="pone.0213190.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Richardson</surname><given-names>ET</given-names></name>, <name><surname>Kelly</surname><given-names>JD</given-names></name>, <name><surname>Sesay</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>The symbolic violence of 'outbreak': A mixed methods, quasi-experimental impact evaluation of social protection on Ebola survivor wellbeing</article-title>. <source><italic toggle="yes">Soc Sci Med</italic></source>
<year>2017</year>; <volume>195</volume>: <fpage>77</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.socscimed.2017.11.018</pub-id>
<?supplied-pmid 29156248?><pub-id pub-id-type="pmid">29156248</pub-id></mixed-citation></ref><ref id="pone.0213190.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Meltzer</surname><given-names>MI</given-names></name>, <name><surname>Atkins</surname><given-names>CY</given-names></name>, <name><surname>Santibanez</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Estimating the future number of cases in the Ebola epidemic&#x02014;Liberia and Sierra Leone, 2014&#x02013;2015</article-title>. <source><italic toggle="yes">MMWR Suppl</italic></source>
<year>2014</year>; <volume>63</volume>(<issue>3</issue>): <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <?supplied-pmid 25254986?><pub-id pub-id-type="pmid">25254986</pub-id></mixed-citation></ref><ref id="pone.0213190.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Butler</surname><given-names>D</given-names></name>. <article-title>Models overestimate Ebola cases</article-title>. <source><italic toggle="yes">Nature</italic></source>
<year>2014</year>; <volume>515</volume>(<issue>7525</issue>): <fpage>18</fpage>
<pub-id pub-id-type="doi">10.1038/515018a</pub-id>
<?supplied-pmid 25373654?><pub-id pub-id-type="pmid">25373654</pub-id></mixed-citation></ref><ref id="pone.0213190.ref054"><label>54</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. Outbreaks Chronology: Ebola Hemorrhagic Fever [Internet]. 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vhf/ebola/resources/outbreak-table.html">http://www.cdc.gov/vhf/ebola/resources/outbreak-table.html</ext-link>.</mixed-citation></ref><ref id="pone.0213190.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Worden</surname><given-names>L</given-names></name>, <name><surname>Wannier</surname><given-names>R</given-names></name>, <name><surname>Hoff</surname><given-names>NA</given-names></name>, <name><surname>Musene</surname><given-names>K</given-names></name>, <name><surname>Selo</surname><given-names>B</given-names></name>, <name><surname>Mossoko</surname><given-names>M</given-names></name>, <name><surname>Okitolonda-Wemakoy</surname><given-names>E</given-names></name>, <name><surname>Muyembe-Tamfum</surname><given-names>JJ</given-names></name>, <name><surname>Rutherford</surname><given-names>GW</given-names></name>, <name><surname>Lietman</surname><given-names>TM</given-names></name>, <name><surname>Rimoin</surname><given-names>AW</given-names></name>, <name><surname>Porco</surname><given-names>TC</given-names></name>, <name><surname>Kelly</surname><given-names>JD</given-names></name>. <article-title>Real-time projections of epidemic transmission and estimation of vaccination impact during an Ebola virus disease outbreak in the Eastern region of the Democratic Republic of Congo</article-title>. <source>BioRxiv</source>. <day>5</day>
<month>11</month>
<year>2018</year>
<pub-id pub-id-type="doi">10.1101/461285</pub-id> Available at: <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/biorxiv/early/2018/11/05/461285.full.pdf">https://www.biorxiv.org/content/biorxiv/early/2018/11/05/461285.full.pdf</ext-link>.</mixed-citation></ref></ref-list></back></article>